Our strategy
Our 2030 GROW strategy focuses on growing our core business while reinvesting for the future
Strategy update 2025
We announced our 2030 strategy update on August 20, 2025.
Company announcement
Conference call slides
Webcast (Strategy update from 17:30)CMD 2024
We hosted our latest Capital Markets Day on June 18, 2024.
Company announcement
Conference call slides
Webcast
Anchored in three strategic pillars, our strategy defines our path to profitable growth, as we expand the biosolutions market and carve our way into the approximately EUR 1 trillion specialty chemicals market.
Novonesis is a pure biology player, with deep scientific specialization in microbiology and industrial fermentation. We are present in a broad range of industries, from food and nutrition to agriculture, household care, and energy. Our biosolutions reach more than two billion people every day.
Demand for our solutions continues to grow across industries and regions
This is driven by a convergence of performance, health attributes and efficiencies, and environmental benefits.
Our biosolutions help customers reduce chemical usage, increase yields, and save energy. In doing so, they improve food security, support healthy living, and boost local economies.
The benefits are clear, and advances in biotechnology are accelerating this convergence, allowing us to develop solutions faster and more effectively. Advanced data, AI, and quantum computing further strengthen discovery, design, and performance prediction across our innovation pipeline.
Uniquely positioned to drive an expanding biosolutions market
Today, the biosolutions market encompasses products like amino acids, vitamins, peptides, enzymes, cultures, yeast, probiotics, and fermented proteins. With our innovative solutions, we are steadily expanding the boundaries of the biosolutions market while carving our way into the EUR 1 trillion addressable specialty chemicals market.
Leveraging our close customer relationships, we provide cutting-edge innovation through co-creation and world-class operational capabilities on a global scale. With these capabilities and powered by our talented employees, we are uniquely positioned to continue expanding the market and deliver sustainable, profitable growth today and in the future.
Long-term financial and sustainability targets
In August 2025, we announced our ambitious 2030 targets and strategic priorities, which set the path for delivering on those long-term ambitions. Our strategy is called GROW, and it is a continuation of our strategic direction.
Three strategic pillars
GROW focuses on growing our core business and making investments to
secure long-term growth. It is anchored in three strategic pillars: ‘Grow the
core’, ‘Enhance our distinctive position’, and ‘Accelerate the biosolutions
market’. Together, they define our path to profitable growth.
Grow the core
Continuing to deliver strong, profitable growth from our core segments is the foundational pillar of our strategy. We operate in a broad range of markets, and we consistently outperform underlying end-market volume growth of 1–2% per year.
Our solutions usually represent a small share of our customers’ cost of goods sold, yet they deliver significant value for end users.This creates room for continuous growth through value-based pricing, increased penetration, upselling, and expanding into adjacent sales areas and geographies. It also allows us to realize synergy potential by leveraging our expanded biological toolbox.
Enhance our distinctive position
We are leading the era of biosolutions with a unique position built on three distinct capabilities: a deep understanding of our customers, innovation leadership, and world-class scale capabilities. To support growth towards 2030 and beyond, we continue to invest in each of them.
Building on our biological expertise, we work closely with our customers – globally and regionally – to deeply understand their needs and translate them into specialized solutions based on biology. Through more than 40 local R&D, application and co-creation centers, we adapt and optimize solutions quickly.
Accelerate the biosolutions market
Our growth allows us to plant future seeds for new areas of biosolutions. This includes selective investment in adjacent and emerging opportunities. These exploratory areas come with significant potential, but also higher risk. Applying a venture-model approach to these explorative opportunities, we continue to invest only when and if we reach milestones on both technology and market-readiness, and when we see a viable path forward.
We see positive traction across our portfolio of exploratory efforts, including commercial sales in processing aids for the biopharma industry, a segment we have been developing for several years.
Dive deeper into our three strategic pillars in the Annual Report 2025.
Our 2030 targets
Organic sales CAGR
Adjusted EBITDA margin
Adjusted ROIC (excluding goodwill)
Reduction in scope 1 and 2 emissions (from 2018 baseline)
Of the underrepresented gender in senior management
Our targets are underpinned by continued investments to secure profitable growth, also beyond 2030
For the strategy period, we are reconfirming our sustainability ambition of People.Planet.Positive., and our sustainability targets. We also maintain our long-term ambitions on gender parity and climate.
Explore more reasons to invest
Sustainable investing
Investing in Novonesis means contributing to a sustainable future through the power of biosolutions.
Spotlight educational sessions
Dive into our educational sessions to learn more about our different businesses.
Whether you're a shareholder or an investment professional, we're here to help.